- Navitas Semiconductor shares rose 11.8% to $13.11 in pre-market trading after being awarded the U.S. government ALATTIS program to develop 10 kV silicon carbide power semiconductor technology.
- AstraZeneca agreed to invest $2 billion in Summit Therapeutics, driving the latter's stock up 21.8% to $18.87 in pre-market trading.
- Other notable pre-market stock movements included BIO-Key International surging 100.7% following a regional partnership, while NewGenIvf Group tumbled 40.9% after pricing a $1.25 million public offering.